Sangamo BioSciences | SGMO - Pre Tax Profit


Sangamo BioSciences reported $-36.05M in Pre-Tax Profit for its fiscal quarter ending in June of 2024.





Pre Tax Profit Change Date
Alaunos Therapeutics USD -7.84M 633K Dec/2023
Alnylam Pharmaceuticals USD 221.65M 60.52M Mar/2026
Alterity Therapeutics Limited AUD -4.74M 3.53M Dec/2024
Amgen USD 1.51B 2.41B Dec/2025
Bayer EUR -3.37B 2.21B Dec/2025
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
Biogen USD 377.7M 433.7M Mar/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Cipla INR 7.49B 4.2B Mar/2026
Clal Biotechnology ILS 86.82M 17.9M Dec/2022
Compugen USD 56.84M 63.78M Dec/2025
CSL USD 2.61B 1.21B Dec/2025
Gilead Sciences USD 2.08B 1.56B Dec/2025
GlaxoSmithKline GBP 2.14B 919M Mar/2026
Grifols EUR 257.85M 190.87M Dec/2024
Ionis Pharmaceuticals USD -93M 135M Mar/2026
J&J USD 7.82B 2.86B Mar/2026
Karyopharm Therapeutics USD -39.9M 9.01M Dec/2025
Merck USD 3.42B 3.32B Dec/2025
Novartis USD 3.84B 802M Mar/2026
Omeros USD -65.12M 21.27M Jun/2024
Pfizer USD 5.18B 6.82B Mar/2026
Roche Holding CHF 4.79B 3.01B Jun/2025
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Sanofi EUR -1.16B 5.5B Dec/2025
Sarepta Therapeutics USD 343.17M 750.85M Mar/2026
Tectonic Therapeutic USD -18.97M 63K Dec/2025
Ultragenyx Pharmaceutical USD -184M 56M Mar/2026
Vertex Pharmaceuticals USD 1.25B 78.1M Mar/2026